BIOMAT Database Logo BIOMAT Database Logo

Niceritrol reduces plasma lipoprotein(a) levels in patients undergoing maintenance hemodialysis. 1993

H Nakahama, and T Nakanishi, and O Uyama, and M Sugita, and M Miyazaki, and T Yokokawa, and K Okamura, and Y Tanaka, and D Shirai
Fifth Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.

Lp(a) is an LDL-like lipoprotein carrying the apoprotein(a) glycoprotein and has recently been recognized to be an independent risk factor for coronary heart disease. We studied plasma Lp(a) levels in 40 patients undergoing maintenance hemodialysis (24 male, 16 female; aged 16-83 years). Fasting plasma Lp(a) levels were measured by an enzyme-linked immunosorbent assay. The median value of plasma Lp(a) concentrations in hemodialysis patients was significantly higher than that of the normal volunteers (26.0 +/- 2.7 vs. 10.8 +/- 3.7 mg/dL, p < .05). Lp(a) levels did not correlate with age, duration of hemodialysis, total cholesterol, triglyceride, HDL cholesterol, or LDL cholesterol. The 11 patients whose plasma Lp(a) concentrations exceeded 20 mg/dL received niceritrol, a prodrug of nicotinic acid, at a dosage of 500 mg t.i.d. for 4 weeks. The plasma Lp(a) levels were significantly lower after 4 weeks of treatment (38.3 +/- 4.2 vs. 31.5 +/- 3.2 mg/dL, p < .01).

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009531 Niceritrol An ester of nicotinic acid that lowers cholesterol and triglycerides in total plasma and in the VLD- and LD-lipoprotein fractions. Pentaerythritol Tetranicotinate,Niceritrol Tetrahydrochloride,Pentaerythritoltetranicotinate,Perycit,Tetrahydrochloride, Niceritrol,Tetranicotinate, Pentaerythritol
D011355 Prodrugs A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug. Drug Precursor,Drug Precursors,Pro-Drug,Prodrug,Pro-Drugs,Precursor, Drug,Precursors, Drug,Pro Drug,Pro Drugs
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005215 Fasting Abstaining from FOOD. Hunger Strike,Hunger Strikes,Strike, Hunger,Strikes, Hunger
D005260 Female Females
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

H Nakahama, and T Nakanishi, and O Uyama, and M Sugita, and M Miyazaki, and T Yokokawa, and K Okamura, and Y Tanaka, and D Shirai
Pentaerythritol tetranicotinate (niceritrol) decreases plasma lipoprotein(a) levels.
April 1997, Metabolism: clinical and experimental,
H Nakahama, and T Nakanishi, and O Uyama, and M Sugita, and M Miyazaki, and T Yokokawa, and K Okamura, and Y Tanaka, and D Shirai
Serum lipoprotein (a) levels in maintenance hemodialysis patients.
January 1993, Nephron,
H Nakahama, and T Nakanishi, and O Uyama, and M Sugita, and M Miyazaki, and T Yokokawa, and K Okamura, and Y Tanaka, and D Shirai
[Plasma nicotinic acid levels in hemodialysis patients after the administration of niceritrol].
June 1999, Nihon Jinzo Gakkai shi,
H Nakahama, and T Nakanishi, and O Uyama, and M Sugita, and M Miyazaki, and T Yokokawa, and K Okamura, and Y Tanaka, and D Shirai
[Plasma allantoin in patients undergoing maintenance hemodialysis].
April 1996, Nihon Jinzo Gakkai shi,
H Nakahama, and T Nakanishi, and O Uyama, and M Sugita, and M Miyazaki, and T Yokokawa, and K Okamura, and Y Tanaka, and D Shirai
Taurine levels in plasma and blood cells in patients undergoing routine maintenance hemodialysis.
July 1991, American journal of kidney diseases : the official journal of the National Kidney Foundation,
H Nakahama, and T Nakanishi, and O Uyama, and M Sugita, and M Miyazaki, and T Yokokawa, and K Okamura, and Y Tanaka, and D Shirai
[Niceritrol decreases serum phosphate levels in chronic hemodialysis patients].
January 1998, Nihon Jinzo Gakkai shi,
H Nakahama, and T Nakanishi, and O Uyama, and M Sugita, and M Miyazaki, and T Yokokawa, and K Okamura, and Y Tanaka, and D Shirai
[A study on plasma allantoin in patients undergoing maintenance hemodialysis].
July 1993, Nihon Jinzo Gakkai shi,
H Nakahama, and T Nakanishi, and O Uyama, and M Sugita, and M Miyazaki, and T Yokokawa, and K Okamura, and Y Tanaka, and D Shirai
Plasma carnitine levels in patients undergoing hemodialysis.
September 1998, Nephron,
H Nakahama, and T Nakanishi, and O Uyama, and M Sugita, and M Miyazaki, and T Yokokawa, and K Okamura, and Y Tanaka, and D Shirai
Altered plasma free and protein-bound sulfur amino acid levels in patients undergoing maintenance hemodialysis.
April 1987, The American journal of clinical nutrition,
H Nakahama, and T Nakanishi, and O Uyama, and M Sugita, and M Miyazaki, and T Yokokawa, and K Okamura, and Y Tanaka, and D Shirai
Dose-dependent effect of niceritrol on plasma lipoprotein-a.
July 1996, Scandinavian journal of clinical and laboratory investigation,
Copied contents to your clipboard!